Cancer Drug Prices: Mark-ups Surge to 700% as One-Time Price Caps Fail to Curb Exploitation
The promise of affordable life-saving medication remains a distant reality for many cancer patients in India. New data from the National Pharmaceutical Pricing Authority (NPPA) reveals a disturbing trend: despite government intervention, mark-ups on essential anti-cancer drugs have soared to as high as 700%. This evidence has reignited the debate over the effectiveness of the NPPA’s regulatory approach, specifically the reliance on one-time price reductions rather than permanent structural controls.
The Failure of One-Time Interventions
In February 2019, the NPPA implemented a trade margin cap of 30% on the selling price of various anti-cancer medications. The objective was to provide immediate relief to patients by curbing exorbitant pricing. However, a comparative analysis of the 2019 list and the agency’s 2026 data shows that this relief was transient.
Of the 137 anti-cancer drugs identified by the NPPA for recent price reductions, 34 were previously featured in the 2019 mandate. Alarmingly, the latest figures show that most of these drugs have significantly breached the 43% mark-up threshold—a figure equivalent to a 30% trade margin when calculated against the final Maximum Retail Price (MRP). In many instances, the mark-ups have returned to levels even higher than those recorded before the 2019 intervention.
A Cycle of Exploitation
The All-India Drug Action Network (AIDAN), a prominent advocacy group for accessible medicine, has criticized the NPPA’s methodology. Malini Aisola of AIDAN argues that branding these measures as “trade margin capping” is fundamentally misleading.
“It is not a cap. It is just a one-time reduction of MRP by restricting the mark-up,” Aisola noted. The data supports this critique; without a mandate for permanent margin caps and rigorous, consistent monitoring, pharmaceutical companies have successfully allowed prices to drift upward again, neutralizing the gains made seven years ago.
For instance, the drug Pemetrexed saw a drastic price drop in 2019, with its MRP falling from ₹7,000 to ₹800. In the current cycle, its price was reduced from ₹1,095 to ₹297. While the reduction is notable, the pattern indicates that manufacturers are quick to inflate prices once the immediate pressure of a regulatory order subsides. Furthermore, many multinational corporations and originators—those holding the original patents—have shown little to no initiative in lowering prices voluntarily, with some offering negligible reductions across both the 2019 and 2026 mandates.
The Need for Systematic Reform
The current findings present a grim reality: of the 42 drugs monitored since 2019, only five maintained a mark-up of 43% prior to the new order. Four others sat in the 43% to 100% range, while the remaining 39 brands carried mark-ups ranging from 100% to a staggering 700%.
Public health experts argue that unless the NPPA shifts from periodic, one-time price cuts to a robust, permanent ceiling on trade margins, the burden of high-cost chemotherapy and oncology care will continue to push families toward financial catastrophe. As mark-ups continue to climb, the necessity for a transparent, automated, and permanent regulatory mechanism has never been more urgent.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
